Giovanni Pecoraro, Katia Pane, Monica Franzese, Giuliana Beneduce, Antonia De Matteo, Rosanna Parasole, Giovanni Smaldone
{"title":"Uncovering LINC02982: a T-ALL-specific lncrna linking epigenetic regulation and metabolic pathways.","authors":"Giovanni Pecoraro, Katia Pane, Monica Franzese, Giuliana Beneduce, Antonia De Matteo, Rosanna Parasole, Giovanni Smaldone","doi":"10.1186/s12935-026-04433-w","DOIUrl":"10.1186/s12935-026-04433-w","url":null,"abstract":"<p><p>T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive pediatric malignancy with limited molecular biomarkers to guide diagnosis and personalized therapy. Given the critical role of long non-coding RNAs in gene regulation and chromatin dynamics, we investigated whether novel lncRNAs could contribute to T-ALL pathogenesis. Through transcriptomic profiling of patient samples and in-silico validation on public datasets, we identified LINC02982 as a lncRNA selectively overexpressed in T-ALL and specifically enriched in leukemic blasts. Functional silencing of LINC02982 in multiple T-ALL cell lines impaired proliferation, altered cell-cycle progression, and increased apoptosis. Integrative ATAC-seq and RNA-seq analyses revealed widespread changes in chromatin accessibility and gene expression, including deregulation of metabolic genes such as AK4 and PSAT1. Promoter accessibility showed a moderate correlation with transcriptional changes, consistent with a potential cis-regulatory role, while broader transcriptomic alterations suggest additional trans effects. Pathway analysis highlighted metabolic processes, including cholesterol biosynthesis, as significantly affected, with LINC02982 depletion reducing expression of key pathway genes and intracellular cholesterol levels. These findings identify LINC02982 as a T-ALL-associated lncRNA linked to transcriptional and metabolic alterations, supporting its potential biological relevance in leukemic cellular regulation and warranting further investigation in larger clinical cohorts.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13711947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149285438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Md Rafee Ur Rahman, Xin Chen, Ananya Podder, Ximing Xu
{"title":"The evolving role of TP53 mutation in hepatocellular carcinoma (HCC).","authors":"Md Rafee Ur Rahman, Xin Chen, Ananya Podder, Ximing Xu","doi":"10.1186/s12935-026-04408-x","DOIUrl":"10.1186/s12935-026-04408-x","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is one of the most common cancer types globally, which is characteristically aggressive, with a poor prognosis and a high mortality rate. The pathways leading to the development and progression of this fatal disease have been studied at the macro and micromolecular levels, where the interplay of multiple factors has been observed in multistep processes. Invariably, all factors at some point trigger mutations in specific genes that contribute to the development and progression of hepatic tumors. Decades of research have demonstrated that, among all genetic variations, mutation in the TP53 gene is the most frequent phenomenon, attracting global interest in cancer research. Driven by certain external and internal factors, the mutation transforms TP53 into an active oncogene with both gain-of-function (GOF) and loss-of-function (LOF) properties, collectively exerting a robust carcinogenic effect. The key mechanisms involved in this process include the P53-MDM2 negative feedback loop, the CDK4/cyclin D1-PIN1-FBW7a-c-Myc axis, profound immune modulation, and the development of cancer stemness, collectively shaping tumor behavior. Given that patients with p53 mutations often present with advanced-stage, it is crucial to adopt mutation-centric subgroup stratification to achieve prognostic precision and therapeutic success. However, emerging techniques are facing significant challenges due to the diverse heterogeneity and immune modulation caused by the mutation, making it difficult to design an effective management scheme. In recent years, several strategies have shown promising results in preclinical and early clinical settings, and combining them with established frontline therapies or incorporating them into preventive measures may open new possibilities. Existing studies largely highlight the mutation from molecular and clinicopathological perspectives, rather than undertaking an inclusive examination and meaningful translation for prospective clinical advancement. This review attempts to fully capture the unfolding role of p53 mutations, primarily based on the literature from the last 10 years, and provides a comprehensive perspective on both mechanistic insights and translational aspects.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13711869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Saumil Shah, Jan Mueller, Emanuel Vogel, Michael Raatz, Steffen Boettcher, Arne Traulsen, Markus G Manz, Philipp M Altrock
{"title":"Quantifying target antigen-dependent CAR T-cell performance against AML.","authors":"Saumil Shah, Jan Mueller, Emanuel Vogel, Michael Raatz, Steffen Boettcher, Arne Traulsen, Markus G Manz, Philipp M Altrock","doi":"10.1186/s12935-026-04419-8","DOIUrl":"10.1186/s12935-026-04419-8","url":null,"abstract":"<p><p>Chimeric Antigen Receptor (CAR) T-cell therapy has transformed cancer immunotherapy by genetically engineering T-cells to target tumor antigens. Acute myeloid leukemia (AML) presents unique challenges due to resistance mechanisms, especially in patients with TP53 loss mutations. The complex dynamics of CAR T-cell expansion remain poorly understood. The field lacks validated quantitative frameworks to systematically evaluate different CAR T-cell target constructs, such as CD33, CD123, and CD371, against resistant AML variants. We address this gap by combining mathematical modeling with in vitro assay data and Bayesian inference. We select, train, and validate a two-compartment deterministic mathematical model that describes the nonlinear dynamics of target AML and CAR T cells, accounting for expansion, killing, and exhaustion. Using Bayesian inference, we train and select the best-performing functional form for CAR T expansion and then validate it on unseen data. Our framework selects a CAR T-cell expansion model that accounts for handling time and T-cell self-interference, highlighting that expansion is a dynamic process in which target-cell handling time and T-cell crowding negatively affect T-cell expansion. Analysis of posterior parameter distributions reveals target-antigen-specific responses against TP53-deficient AML. For instance, CD33-targeting CARs have reduced attack rates against TP53-deficient cells, while CD123- and CD371-targeting CARs show moderately increased attack rates; however, the former exhibit higher death rates, and the latter have increased handling times, impeding efficacy. This target-dependent form of resistance challenges the assumption of uniform performance and reveals a unifying nonlinear expansion model for integrated, yet antigen-specific, preclinical predictions of efficacy.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13420862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zoltan Adam, Kitti Garai, Abigel Sebok-Tornai, Marta Wilhelm, Krisztian Kvell
{"title":"From motion to molecules: exercise-triggered large EVs suppress oncogenic signaling in lung adenocarcinoma cells - an in vitro pilot study.","authors":"Zoltan Adam, Kitti Garai, Abigel Sebok-Tornai, Marta Wilhelm, Krisztian Kvell","doi":"10.1186/s12935-026-04429-6","DOIUrl":"10.1186/s12935-026-04429-6","url":null,"abstract":"<p><strong>Background: </strong>Although regular physical activity is known to reduce cancer risk, the circulating molecular mechanisms responsible for these effects remain incompletely defined. Exercise alters the release and composition of extracellular vesicles (EVs), suggesting a role in systemic anti-tumor signaling. However, the contribution of large EVs (L-EVs) ─ a distinct and understudied EV subtype ─ to the regulation of lung adenocarcinoma cell behaviour has not been examined to date.</p><p><strong>Methods: </strong>L-EVs were isolated from platelet-free plasma of healthy, regularly exercising older adults with over 25 years of training history (aged 61 ± 2 years), collected at rest (Pre) and after (Post) an acute endurance exercise bout. EV fractions were characterized via transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and antibody-based profiling. PC9 lung adenocarcinoma cells were incubated with plasma-derived L-EV-enriched fractions for 24 h. Cell viability and metabolic activity were evaluated using ATP-based luminescence and XTT assays following L-EV treatment. miRNA and gene expression changes were assessed using RT-qPCR with TaqMan arrays. Differentially expressed miRNAs (DEmiRs) and genes (DEGs) were analysed using Ingenuity Pathway Analysis (IPA) to evaluate regulatory networks and predict functional outcomes.</p><p><strong>Results: </strong>Exercise significantly increased plasma nanoparticle concentration (mean increase of 5.05 × 10⁷ ± 9.99 × 10⁶ particles/mL; p < 0.001, Cohen's d = 1.685). TEM and NTA confirmed successful isolation of L-EVs, with mode sizes of 136.1 ± 23.6 nm pre-exercise and 129.5 ± 17.7 nm post-exercise. In PC9 cells, both Pre- and Post-L-EVs reduced metabolic activity compared to control conditions, as demonstrated by ATP-based and XTT assays, indicating a functional impact on cell viability (p < 0.001). Transcriptomic analysis revealed distinct expression changes between conditions. Post-L-EVs downregulated oncogenic and immune evasion-associated genes (MAX, FASLG, and ELK1) while upregulating pro-apoptotic and cell cycle inhibitory genes (CASP9, FADD, and CDKN2B). Several DEmiRs, including miR-21-5p, miR-301b-3p, and miR-193a-3p, shifted in directions opposite to their known oncogenic patterns in NSCLC, suggesting a tumor-suppressive influence. IPA predicted enhanced apoptotic signaling and reduced metastatic potential following Post-L-EV treatment.</p><p><strong>Conclusion: </strong>Exercise-conditioned plasma-derived enriched L-EVs modulate gene and miRNA expression in lung adenocarcinoma cells toward a tumor-suppressive profile. By attenuating oncogenic and immune-evasion signals while enhancing apoptotic and cell cycle-inhibitory pathways, Post-L-EVs offer preliminary mechanistic insight into the anti-cancer potential of physical activity. Their origin from older adults engaged in long-term exercise highlights the systemic benefits of sustained activity and the promi","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13700146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sphingolipid metabolic subtyping defines SPHK1 as an oncogene and characterizes immunosuppressive TME features in gastric cancer.","authors":"Zeyu Wang, Zhuying Yue, Chengkai Jiang","doi":"10.1186/s12935-026-04401-4","DOIUrl":"10.1186/s12935-026-04401-4","url":null,"abstract":"<p><p>Gastric cancer (GC) exhibits profound heterogeneity and poor clinical outcomes, underscoring the need for improved prognostic stratification and deeper insights into metabolism-immune interactions within the tumor microenvironment (TME). Although sphingolipid metabolic reprogramming is known to influence TME remodeling, systematic GC subtyping based on sphingolipid metabolism-related genes (SMGs) and the spatial regulatory roles of key metabolic enzymes remain insufficiently characterized. Using TCGA RNA sequencing data, we performed unsupervised clustering of SMGs and identified two metabolic subtypes. Cluster A was marked by upregulated sphingolipid metabolism, extensive extracellular matrix remodeling, and enrichment of immunosuppressive pathways, corresponding to significantly worse survival. Cluster B showed enrichment of energy metabolic programs and increased inflammatory immune infiltration, aligning with a more favorable prognosis. Spatial transcriptomic analysis revealed SPHK1 enrichment at the tumor invasive front, where high SPHK1 expression correlated with increased dendritic cell and neutrophil infiltration but not CD8<sup>+</sup> T cell accumulation, suggesting a myeloid-dominant immunosuppressive niche. Functionally, SPHK1 knockdown suppressed GC cell proliferation and migration, increased E-cadherin, decreased mesenchymal markers, and inhibited TGF-β1 signaling, confirming its role in EMT and tumor progression. Collectively, these findings identify sphingolipid metabolic remodeling and aberrant SPHK1 activation as key drivers of GC immune evasion and potential therapeutic vulnerabilities.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maria Teresa Rocchetti, Domenica Mangieri, Giuseppe Spano, Daniela Fiocco
{"title":"Molecular mechanisms involved in the anticancer activities of probiotics and postbiotics.","authors":"Maria Teresa Rocchetti, Domenica Mangieri, Giuseppe Spano, Daniela Fiocco","doi":"10.1186/s12935-026-04411-2","DOIUrl":"10.1186/s12935-026-04411-2","url":null,"abstract":"<p><p>Probiotics promote host health and have shown potential as both prophylactics and adjuvants for the treatment of several human diseases. Therefore, medical interest in these microorganisms has increased rapidly. Recently, probiotics along with postbiotics, i.e., their inanimated counterparts, have been explored for their capacity to treat cancer, a vast group of diseases characterized by uncontrolled cell proliferation, which represents a major global health burden and is the second leading cause of death worldwide. The present review collects and discusses recent preclinical studies addressing the anticancer action of probiotics and postbiotics from lactic acid bacteria and bifidobacteria, and describes the molecular mechanisms by which they hamper some major hallmarks of tumor cells, i.e., through stimulation of apoptosis, blockade of proliferation and the cell cycle, inhibition of metastasis, metabolic interference, activation of the host anti-cancer immune response. The medical use of probiotics should rely on an extensive understanding of the molecular and cellular mechanisms underlying their anticancer activities. Accordingly, this review aims to provide insights into the advancements and limitations of the current research in this field, which is strongly needed to provide solid rationales for the prospective clinical use of probiotics in cancer.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13689291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"High xCT expression indicates poor prognosis and chemoradiotherapy resistance in rectal cancer patients.","authors":"Yingru Li, Heng LiuFu, Zhilong Yuan, Wenchang Gan, Shaoyong Peng, Jinhong Li, Haiyang Xin, Canfeng Cai, Bing Zeng","doi":"10.1186/s12935-026-04428-7","DOIUrl":"10.1186/s12935-026-04428-7","url":null,"abstract":"<p><strong>Background: </strong>xCT/SLC7A11, an amino acid transporter, is implicated in various cancers. However, its role in rectal cancer remains unclear. This study aimed to explore its predictive value for prognosis and chemoradiotherapy response in rectal cancer patients.</p><p><strong>Methods and materials: </strong>xCT expression was assessed using immunohistochemistry and RT-qPCR, and its associations with clinicopathological features and prognosis were analyzed. Single-cell RNA sequencing data and the TIMER platform were used to examine xCT's correlation with immune cell infiltration. A prognostic nomogram model was developed and evaluated with ROC, calibration, and decision curve analysis. Cell proliferation and cytotoxicity assays were conducted to assess xCT's role in ferroptosis and chemoradiotherapy sensitivity.</p><p><strong>Results: </strong>xCT expression was elevated in rectal cancer tissues and correlated with adverse clinicopathological features, including tumor regression grade (P < 0.001). Single-cell and immune infiltration analyses indicated that xCT was associated with the immune microenvironment. High xCT expression predicted worse overall and disease-free survival, and multivariate analysis confirmed it as an independent prognostic factor. The xCT-based nomogram accurately predicted 1- and 3-year survival rates. Additionally, xCT knockout inhibited cell proliferation and enhanced chemoradiotherapy sensitivity in vitro and in vivo by promoting ferroptosis.</p><p><strong>Conclusion: </strong>High expression of xCT was associated with poor prognosis and chemoradiotherapy response in rectal cancer, representing a potential prognostic marker and therapeutic target.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Capsaicin enhances chemosensitivity and mitigates MMP11-driven aggressiveness in human bladder cancer.","authors":"Te-Fu Tsai, Hao-Chiun Chang, Yen-You Lin, Yen-Chen Chen, Win-Ping Deng, Thomas I-Sheng Hwang, Kuang-Yu Chou, Chao-Yen Ho, Hung-En Chen, Chih-Hsin Tang, Shih-Wei Wang, An-Chen Chang","doi":"10.1186/s12935-026-04397-x","DOIUrl":"10.1186/s12935-026-04397-x","url":null,"abstract":"<p><p>Bladder cancer (BLCA) is the second most common malignant cancer of the male urological system. BLCA is characterized by a high rate of recurrence. Capsaicin is increasingly being used in cancer treatment. This study analyzed the inhibitory effects of capsaicin on cell invasiveness and examined whether capsaicin enhances the chemosensitivity of BLCA. High concentrations of capsaicin induced apoptosis in cancer cells. Co-administration of capsaicin with various chemotherapy drugs (cisplatin, epirubicin, and mitomycin C) increased cancer cell sensitivity to chemotherapy. At lower concentrations, capsaicin effectively inhibited cell invasiveness by downregulating MMP11 expression. Mechanistically, capsaicin suppressed MMP11 expression through the transient receptor potential vanilloid 1 receptor and the p38/extracellular signal-regulated kinase/c-Jun signaling pathway. Functional analysis revealed a positive correlation between the expression level of MMP11 and various ontogenetic properties of BLCA. MMP11 expression was positively correlated with clinical staging, muscle-invasive bladder cancer, lymphatic metastasis, and poor prognosis in patients with BLCA. These findings suggest that MMP11 has potential as a clinical prognostic marker for BLCA. Finally, capsaicin demonstrated significant tumor growth suppression and enhanced chemosensitivity in vivo. Taken together, capsaicin may promote apoptosis, inhibit cell invasion in vitro, and suppress tumor growth in vivo. Combining capsaicin with first-line chemotherapeutic drugs may enhance their efficacy against BLCA, and therefore, which indicates that capsaicin has promise as a clinical medication.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shijian Wang, Baorui Tian, Huimin Liu, Chen Zhang, Jianan Wang, Xin Song, Ruibing Li, Haoran Guo, Nan Wang, Wanjun Zhang, Yongjun Piao, Yi Shi, Rong Xiang
{"title":"Quantitative proteomic landscape reveals the role of CSPG5 in the recurrence of glioma.","authors":"Shijian Wang, Baorui Tian, Huimin Liu, Chen Zhang, Jianan Wang, Xin Song, Ruibing Li, Haoran Guo, Nan Wang, Wanjun Zhang, Yongjun Piao, Yi Shi, Rong Xiang","doi":"10.1186/s12935-026-04430-z","DOIUrl":"10.1186/s12935-026-04430-z","url":null,"abstract":"<p><strong>Background: </strong>The high recurrence rate of glioma accounts for the majority of glioma-related deaths. Although numerous studies have investigated genomic and transcriptomic alterations, high-resolution quantitative proteomic profiling studies remain limited.</p><p><strong>Methods: </strong>A total of 63 pairs of primary and recurrent formalin-fixed paraffin-embedded glioma tissues (WHO grade II-IV) were collected. Proteomic profiles were generated by data-independent acquisition mass spectrometry (DIA-MS). Differentially expressed proteins were validated using publicly available databases, immunohistochemistry, and Western blotting. The effects of CSPG5 on glioma cell proliferation and invasion were assessed in vitro and in an orthotopic mouse model. Protein-protein interactions were examined by co-immunoprecipitation, and the influence of CSPG5 on ErbB2 degradation was evaluated by immunofluorescence and quantitative PCR.</p><p><strong>Results: </strong>Two distinct proteomic clusters (Cluster 1 and Cluster 2) associated with glioma recurrence were identified. Chondroitin sulfate proteoglycan 5 (CSPG5) was markedly down-regulated in recurrent tumors. Overexpression of CSPG5 significantly inhibited glioma cell proliferation and invasion in vitro and reduced tumor burden in vivo. Mechanistically, CSPG5 interacted with ErbB2 and promoted its lysosomal degradation, leading to attenuated PI3K-AKT and ERK signaling.</p><p><strong>Conclusions: </strong>CSPG5 acts as a novel suppressor of ErbB2 signaling; its loss facilitates ErbB2 hyperactivation and thereby promotes glioma recurrence.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"26 1","pages":""},"PeriodicalIF":7.0,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13681961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}